

Reference: FOI.ICB-2223/041

**Subject: Procurement of GP Direct Access Pathology Services** 

I can confirm that the ICB does hold the information requested; please see responses below:

QUESTION	RESPONSE
Please list the pathology providers, including NHS organisations, which you used during financial year 2021/22 to provide GP direct access pathology services (list any provider with a spend in the year greater than £25,000)	<ul> <li>Public Health England (now UK Health Security Agency)</li> <li>University Hospitals Bristol and Weston NHS Foundation Trust (UHBW)</li> <li>North Bristol NHS Trust (NBT)</li> <li>Royal United Hospital (RUH) Bath</li> </ul>
Please provide the amount spent with each provider on GP direct access pathology during the year 2021/22.	<ul> <li>Public Health England (now UK Health Security Agency) - £1.116m</li> <li>The following are based on 2019/20 + 3.43% inflation according to the temporary NHS England COVID-19 financial regime guidance:</li> <li>UHBW - £7.188m</li> <li>NBT - £12.804m</li> </ul>
Please state which of following methods for calculating payment best describes the contractual arrangement between the CCG and each provider:	RUH Bath - £0.108m  Public Health England (Fixed payment amount agreed for the year, but adjusted if volumes are higher or lower than expected by a marginal price per test).



<ul> <li>Amount paid for direct access pathology not explicitly stated, ie included within larger overall contract</li> <li>Fixed payment amount for pathology agreed for the year</li> <li>Fixed payment amount agreed for the year, but adjusted if volumes are higher or lower than expected</li> <li>Payment calculated based on a cost per specialty, eg £X per blood science test, £Y per microbiology sample, £Z per histology case</li> <li>Payment calculated on a price per specific test, eg £X for Urea and Electrolytes, £Y for full blood count, £Z for MRSA test</li> </ul>	Fixed payment for the year following NHS England COVID-19 financial regime guidance:  UHBW  NBT  RUH Bath
Have the authority undertaken a procurement advertised via OJEU for GP direct access pathology during the past five years? If so, please provide link.	No

The information provided in this response is accurate as of 1 September 2022 and has been approved for release by Sarah Truelove, Deputy Chief Executive and Chief Finance Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.